These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9316670)

  • 1. Clinical usefulness of apomorphine in movement disorders.
    Colosimo C; Merello M; Albanese A
    Clin Neuropharmacol; 1994 Jun; 17(3):243-59. PubMed ID: 9316670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New dopaminergic therapies for PD motor complications.
    Larson D; Simuni T
    Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A; Jost WH
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC; Burguera JA
    Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and therapeutic value of apomorphine in Parkinsonian patients.
    Sharma JC; Macnamara L; Hasoon M; Vassallo M
    Int J Clin Pract; 2004 Nov; 58(11):1028-32. PubMed ID: 15605666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On demand therapy for Parkinson's disease patients: Opportunities and choices.
    Hauser RA; LeWitt PA; Comella CL
    Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine in dopaminergic therapy.
    Subramony JA
    Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ; Kulisevsky J
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D
    Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Apomorphine].
    Esteban Muñoz J
    Neurologia; 1995 Oct; 10(8):330-7. PubMed ID: 8554783
    [No Abstract]   [Full Text] [Related]  

  • 18. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
    Ferraz HB; Azevedo-Silva SM; Borges V; Rocha MS; Andrade LA
    Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
    Jenner P; Katzenschlager R
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.